Microbiota Restoration Therapy™ (MRT™) Drug Platform
Microbiota Restoration Therapy (MRT) drug platform is the Rebiotix drug platform for delivering healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease.
The Rebiotix clinical program assessing RBX2660 for recurrent C. diff. is at the most advanced stage of development of any microbiota-based drug being investigated under a U.S. Food and Drug Administration Investigational New Drug application.
The normal ‘healthy’ gut contains trillions of microbes working symbiotically to maintain human health. Targeting the human gut microbiota to treat disease is an expanding medical frontier.
MRT™ drug platform has potential to impact clinical practice by treating disease with an entirely new category of drugs.